Table 4.
Benefits and drug costs over 1-year to a practice population of 10,000 resulting from the introduction of these treatments assuming the incremental benefit of the drugs
| Number Needed to Treat (NNT) | Number to be Treated in your Population (NTP) | Number of Events Prevented in your Population (NEPP) | Total drug cost (€) | Drug cost per death prevented (€) | ||
| MI | ||||||
| ACE-I | 69 | 53 | 0.76 | 5,292 | 6,944 | |
| BB | 48 | 84 | 1.74 | 3,793 | 2,174 | |
| Statin | 53 | 120 | 2.26 | 46,150 | 20,423 | |
| Aspirin | 93 | 37 | 0.40 | 410 | 1,019 | |
| MI + CHF | ||||||
| ACE-I | 23 | 3 | 0.15 | 336 | 2,299 | |
| BB | 16 | 9 | 0.55 | 406 | 739 | |
| Spironolactone | 11 | 12 | 1.00 | 1,663 | 1,655 |
MI myocardial Infarction CHF Heart Failure ACE-I ACE Inhibitor BB beta blocker